seroquel xr 50 mg
cheplapharm arzneimittel gmbh, nemecko - kvetiapín - 68 - antipsychotica (neuroleptica)
seroquel xr 200 mg
cheplapharm arzneimittel gmbh, nemecko - kvetiapín - 68 - antipsychotica (neuroleptica)
seroquel xr 300 mg
cheplapharm arzneimittel gmbh, nemecko - kvetiapín - 68 - antipsychotica (neuroleptica)
rosuvastatin mylan 5 mg
mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica
rosuvastatin mylan 10 mg
mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica
rosuvastatin mylan 20 mg
mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica
rosuvastatin mylan 40 mg
mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica
sorvasta 5 mg
krka, d.d., novo mesto, slovinsko - rosuvastatín - 31 - hypolipidaemica
cortiment 9 mg
ferring slovakia s.r.o., slovensko - budezonid - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
ultomiris
alexion europe sas - ravulizumab - hemoglobinúria, paroxysmálna - selektívne imunosupresíva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.